Find verified Linagliptin API manufacturers, suppliers, and distributors across the globe. Explore companies that offer high-purity Linagliptin for pharmaceutical use, along with product details, certifications, and reliable sourcing options. Compare prices, check availability, and connect directly with trusted suppliers for Linagliptin API.
Alternate Names: Linagliptina, Tradjenta, Trajenta
CAS No: 668270-12-0
PubChem CID: 10096344
Mol Formula: C25H28N8O2
Mol Weight: 472.5 g/mol
IUPAC Name: 8-[(3R)-3-aminopiperidin-1-yl]-7-but-2-ynyl-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]purine-2,6-dione
API Description: Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes. Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin was approved by the FDA on May 2, 2011.
